Company intelligence / Profile preview

Elevation Oncology, Inc.

Boston, Massachusetts, United Stateselevationoncology.com ↗

Ownership: Private
Employees: ~34
Development stage: Phase 1

Overview

In March 2025, Elevation Oncology discontinued development of its lead candidate EO-3021 after Phase 1 study showed an objective response rate of 22.2% in gastric/GEJ cancer patients, which was deemed non-competitive. The company is now focusing on EO-1022, with an IND filing planned for 2026[10].

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

2 assets

EO-1022

Pre-clinical

Indications: Solid tumors, Breast cancer

1 more asset in the full pipeline.

Partnerships

CSPC Megalith Biopharmaceutical Co., Ltd. (license agreement for EO-3021)

Beyond the preview

Go deeper on Elevation Oncology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elevation Oncology, Inc..